Prosthesis Mismatch in TAVR: It’s Real Impact

Prosthesis-patient mismatch (PPM) was initially proposed by Rahimtoola and reintroduced by Pirabot.

La prudencia es buena consejera para decidir una transfusión en el TAVI

PPM is the indexed effective orifice area in relation to body surface area, cutoff value being 0.85 cm2/m2, and <0.70 cm2/m2for obese patients. PPM is considered moderate if indexed effective orifice area is 0.65-0.85 cm2/m2 and severe when <0.65 cm2/m2 

Research studies on surgical prosthesis have associated PPM with higher mortality at short, mid and long term. 

There are few studies on post TAVR PPM. Unlike surgical prosthesis, its impact remains to be shown. 

The current study is a meta-analysis of 23 studies with a total 81969 patients. 19612 presented some degree of PPM (23.9%).

Mortality was higher in patients presenting moderate/severe PPM (HR: 1.09 [95% CI: 1.04-1.14]; P < 0.001).

Within the first 30 months, mortality was higher in patients with moderate to severe PPM (HR: 1.1 [95% CI: 1.05-1.16]; P < 0.001). After 30 days, even though mortality was slightly higher, it did not reach statistical significance (HR 0.83 [95% CI: 0.68-1.01]; P = 0.064).

Read also: AQCA Study: Pre-PCI Virtual QFR for Planning PCI vs. Conventional Angiography.

Additionally, PPM moderate and severe were looked at separately, resulting in higher mortality the with more severe PPM, vs. patients with no PPM (HR: 1.25 [95% CI: 1.16-1.36]; P < 0.001). However, this was not the case when looking at moderate PPM (HR: 1.03 [95% CI: 0.96-1.10]; P = 0.398). 

Conclusion

Severe PPM was associated to higher mortality at TAVR followup (unlike moderate PPM). These outcomes call for strategies to prevent severe PPM. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement Meta-Analysis of Kaplan-Meier–Derived Individual Patient Data.

Reference: Michel Pompeu Sá, et al. J Am Coll Cardiol Img 2023;16:298–310.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....